Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030105 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers
A Phase 1 study, sponsored by Tetra Discovery Partners.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03030105: Completed Phase 1 study, sponsored by Tetra Discovery Partners.
NCT03030105 is a Phase 1 study that has completed, run by Tetra Discovery Partners. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03030105, a Phase 1 study, has completed, sponsored by Tetra Discovery Partners.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and additivity of BPN14770 50 mg to donepezil 10 mg in reversing scopolamine effects will also be evaluated.
Interventions
- DRUG Donepezil
- DRUG BPN14770
- DRUG BPN14770 placebo
- DRUG Donepezil placebo
- DRUG Scopolamine 0.6 MG/ML
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
What the finished NCT03030105 record still lists
NCT03030105 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 5 interventions - of which Donepezil is the first listed.
NCT03030105 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03030105 about?
NCT03030105 is a clinical study titled "Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers". This is a Phase 1, randomized, double-blind, placebo-controlled, 6-period crossover study to evaluate the effects of BPN14770 10 mg and 50 mg in reversing scopolamine-induced cognitive impairment in healthy volunteers. A positive control, donepezil 10 mg, will be included, and additivity of BPN14770...
What is the current status of trial NCT03030105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-01. Estimated completion is 2017-06.
What interventions are being tested in trial NCT03030105?
The interventions under investigation include: Donepezil (DRUG), BPN14770 (DRUG), BPN14770 placebo (DRUG), Donepezil placebo (DRUG), Scopolamine 0.6 MG/ML (DRUG).
Who is sponsoring clinical trial NCT03030105?
This trial is sponsored by Tetra Discovery Partners, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03030105's enrollment target sits among peer trials
38 1197th of 2000 higher than 797 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia